Drug Patents Expiring in 2042

1. Axumin patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11980674 BLUE EARTH Imaging of metastatic or recurrent cancer
Apr, 2042

(17 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 27, 2021

Drugs and Companies using FLUCICLOVINE F-18 ingredient

NCE-1 date: 27 May, 2020

Market Authorisation Date: 27 May, 2016

Treatment: Positron emission tomography diagnostic agent in adults with suspected prostate cancer recurrence based on elevated blood prostate specific antigen levels following prior treatment

Dosage: SOLUTION

More Information on Dosage

AXUMIN family patents

Family Patents

2. Ayvakit patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US12060354 BLUEPRINT MEDICINES Crystalline forms of (S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of making
Mar, 2042

(17 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-863) Jun 16, 2024
New Indication(I-864) Jun 16, 2024
New Chemical Entity Exclusivity(NCE) Jan 09, 2025
New Indication(I-912) May 22, 2026
Orphan Drug Exclusivity(ODE-366) Jan 09, 2027
Orphan Drug Exclusivity(ODE-356) Jun 16, 2028
Orphan Drug Exclusivity(ODE-434) May 22, 2030

Drugs and Companies using AVAPRITINIB ingredient

NCE-1 date: 10 January, 2024

Market Authorisation Date: 16 June, 2021

Treatment: Treatment of unresectable or metastatic gastrointestinal stromal tumor (gist) harboring a platelet-derived growth factor receptor alpha (pdgfra) exon 18 mutation

Dosage: TABLET

More Information on Dosage

AYVAKIT family patents

Family Patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Bortezomib patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11752164 MAIA PHARMS INC Bortezomib compositions
Sep, 2042

(17 years from now)

US11679119 MAIA PHARMS INC Bortezomib compositions
Sep, 2042

(17 years from now)

US12005069 MAIA PHARMS INC Bortezomib compositions
Sep, 2042

(17 years from now)




Drugs and Companies using BORTEZOMIB ingredient

Market Authorisation Date: 27 July, 2022

Treatment: Treatment of adult patients with multiple myeloma

Dosage: SOLUTION

More Information on Dosage

BORTEZOMIB family patents

Family Patents

4. Daybue patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11827600 ACADIA PHARMS INC Crystalline forms of trofinetide
Jul, 2042

(17 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Mar 10, 2028
Orphan Drug Exclusivity(ODE-425) Mar 10, 2030

Drugs and Companies using TROFINETIDE ingredient

NCE-1 date: 11 March, 2027

Market Authorisation Date: 10 March, 2023

Treatment: Treatment of rett syndrome or a symptom thereof

Dosage: SOLUTION

More Information on Dosage

DAYBUE family patents

Family Patents

5. Defencath patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11738120 CORMEDIX Synthesis of taurolidine, purity profiles and polymorphs
Apr, 2042

(17 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 15, 2028
Generating Antibiotic Incentives Now(GAIN) Nov 15, 2033

Drugs and Companies using HEPARIN SODIUM; TAUROLIDINE ingredient

NCE-1 date: 15 November, 2032

Market Authorisation Date: 15 November, 2023

Treatment: NA

Dosage: SOLUTION

More Information on Dosage

DEFENCATH family patents

Family Patents

6. Exparel patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11931459 PACIRA PHARMS INC Treatment of pain in pediatric patients by administration of sustained-release liposomal anesthetic compositions
Mar, 2042

(17 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Oct 28, 2014
New Indication(I-771) Apr 06, 2021
New Patient Population(NPP) Mar 22, 2024
New Indication(I-929) Nov 09, 2026

Drugs and Companies using BUPIVACAINE ingredient

Market Authorisation Date: 28 October, 2011

Treatment: A method of treating pain by administering bupivacaine via local infiltration in pediatric patients aged 6 to less than 12 years old undergoing cardiac surgery

Dosage: INJECTABLE, LIPOSOMAL

How can I launch a generic of EXPAREL before it's drug patent expiration?
More Information on Dosage

EXPAREL family patents

Family Patents

7. Galafold patent expiration

Can you believe GALAFOLD received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11833164 AMICUS THERAP US Methods of treating Fabry disease in patients having a mutation in the GLA gene
Jan, 2042

(17 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Aug 10, 2023
Orphan Drug Exclusivity(ODE-205) Aug 10, 2025

Drugs and Companies using MIGALASTAT HYDROCHLORIDE ingredient

NCE-1 date: 10 August, 2022

Market Authorisation Date: 10 August, 2018

Treatment: The treatment of fabry patients

Dosage: CAPSULE

How can I launch a generic of GALAFOLD before it's drug patent expiration?
More Information on Dosage

GALAFOLD family patents

Family Patents

8. Lumryz patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11583510 AVADEL CNS Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
Feb, 2042

(17 years from now)

US11779557 AVADEL CNS Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
Mar, 2042

(17 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) May 01, 2026
Orphan Drug Exclusivity(ODE-431) May 01, 2030
Orphan Drug Exclusivity(ODE-494) Oct 16, 2031

Drugs and Companies using SODIUM OXYBATE ingredient

Market Authorisation Date: 01 May, 2023

Treatment: Treatment of narcolepsy, cataplexy or excessive daytime sleepiness using a once-nightly gamma-hydroxybutyrate formulation; Treatment of cataplexy or excessive daytime sleepiness in patients with narco...

Dosage: FOR SUSPENSION, EXTENDED RELEASE

More Information on Dosage

LUMRYZ family patents

Family Patents

9. Ogsiveo patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11612588 SPRINGWORKS Chlorinated tetralin compounds and pharmaceutical compositions
Jul, 2042

(17 years from now)

US12110277 SPRINGWORKS Synthesis of nirogacestat
Jul, 2042

(17 years from now)

US11504354 SPRINGWORKS Chlorinated tetralin compounds and pharmaceutical compositions
Jul, 2042

(17 years from now)

US11807611 SPRINGWORKS Chlorinated tetralin compounds and pharmaceutical compositions
Sep, 2042

(17 years from now)

US11844780 SPRINGWORKS Chlorinated tetralin compounds and pharmaceutical compositions
Sep, 2042

(17 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 27, 2028
ODE*(ODE*) Nov 27, 2030
Orphan Drug Exclusivity(ODE-452) Nov 27, 2030

Drugs and Companies using NIROGACESTAT HYDROBROMIDE ingredient

NCE-1 date: 28 November, 2027

Market Authorisation Date: 27 November, 2023

Treatment: Treatment of adult patients with progressing desmoid tumors

Dosage: TABLET

More Information on Dosage

OGSIVEO family patents

Family Patents

10. Ponvory patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11951097 VANDA PHARMS INC Methods of treating multiple sclerosis
Oct, 2042

(17 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Mar 18, 2026

Drugs and Companies using PONESIMOD ingredient

NCE-1 date: 18 March, 2025

Market Authorisation Date: 18 March, 2021

Treatment: Treatment of relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults being treated with a ...

Dosage: TABLET

More Information on Dosage

PONVORY family patents

Family Patents

11. Qinlock patent expiration

Can you believe QINLOCK received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11779572 DECIPHERA PHARMS Methods of treating gastrointestinal stromal tumors
Oct, 2042

(17 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 15, 2025
Orphan Drug Exclusivity(ODE-298) May 15, 2027

Drugs and Companies using RIPRETINIB ingredient

NCE-1 date: 15 May, 2024

Market Authorisation Date: 15 May, 2020

Treatment: Treatment of gastrointestinal stromal tumors in patients having pre-existing severe hepatic impairment and suffering from an adverse event while being administered ripretinib daily

Dosage: TABLET

More Information on Dosage

QINLOCK family patents

Family Patents

12. Rezurock patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US12097202 KADMON PHARMS LLC Methods of administering Belumosudil for treatment of chronic graft versus host disease
Jul, 2042

(17 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jul 16, 2026
Orphan Drug Exclusivity(ODE-362) Jul 16, 2028

Drugs and Companies using BELUMOSUDIL MESYLATE ingredient

NCE-1 date: 16 July, 2025

Market Authorisation Date: 16 July, 2021

Treatment: Treatment of chronic graft-versus-host disease (chronic gvhd) after failure of at least two prior lines of systemic therapy in adult and pediatric patients 12 years and older with a grade 3 infection ...

Dosage: TABLET

More Information on Dosage

REZUROCK family patents

Family Patents

13. Sezaby patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11857683 SUN PHARM INDS INC Stabilization of phenobarbital sodium for injection
Apr, 2042

(17 years from now)




Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-414) Nov 17, 2029

Drugs and Companies using PHENOBARBITAL SODIUM ingredient

Market Authorisation Date: 17 November, 2022

Treatment: Method of treating neonatal seizures

Dosage: POWDER

More Information on Dosage

SEZABY family patents

Family Patents

14. Sunosi patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11793776 AXSOME MALTA Methods of administering solriamfetol to lactating women
Dec, 2042

(18 years from now)

US11771666 AXSOME MALTA Methods of administering solriamfetol to lactating women
Dec, 2042

(18 years from now)

US11771667 AXSOME MALTA Methods of administering solriamfetol to lactating women
Dec, 2042

(18 years from now)

US12064411 AXSOME MALTA Methods of administering solriamfetol to lactating women
Dec, 2042

(18 years from now)

US12102609 AXSOME MALTA Methods of administering solriamfetol to lactating women
Dec, 2042

(18 years from now)

US12090126 AXSOME MALTA Methods of administering solriamfetol to lactating women
Dec, 2042

(18 years from now)

US11872203 AXSOME MALTA Methods of administering solriamfetol to lactating women
Dec, 2042

(18 years from now)

US12005036 AXSOME MALTA Methods of administering solriamfetol to lactating women
Dec, 2042

(18 years from now)

US11872204 AXSOME MALTA Methods of administering solriamfetol to lactating women
Dec, 2042

(18 years from now)

US12036194 AXSOME MALTA Methods of administering solriamfetol to lactating women
Dec, 2042

(18 years from now)

US11779554 AXSOME MALTA Methods of administering solriamfetol to lactating women
Dec, 2042

(18 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jun 17, 2024
Orphan Drug Exclusivity(ODE-254) Jun 17, 2026

Drugs and Companies using SOLRIAMFETOL HYDROCHLORIDE ingredient

NCE-1 date: 18 June, 2023

Market Authorisation Date: 17 June, 2019

Treatment: Treatment of excessive daytime sleepiness in a breast-feeding patient while reducing infant exposure to solriamfetol

Dosage: TABLET

How can I launch a generic of SUNOSI before it's drug patent expiration?
More Information on Dosage

SUNOSI family patents

Family Patents

15. Talicia patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11878011 REDHILL Method for eradicating Helicobacter pylori infection in patients regardless of body mass index
May, 2042

(17 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Nov 01, 2022
Generating Antibiotic Incentives Now(GAIN) Nov 01, 2027

Drugs and Companies using AMOXICILLIN; OMEPRAZOLE MAGNESIUM; RIFABUTIN ingredient

Market Authorisation Date: 01 November, 2019

Treatment: Treatment of helicobacter pylori infection using the administered dosage forms in adults with different body mass index determinations

Dosage: CAPSULE, DELAYED RELEASE

More Information on Dosage

TALICIA family patents

Family Patents

16. Tezruly patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11224572 NOVITIUM PHARMA Stable oral liquid composition of terazosin
Jan, 2042

(17 years from now)




Drugs and Companies using TERAZOSIN HYDROCHLORIDE ingredient

Market Authorisation Date: 29 July, 2024

Treatment: Treatment of symptomatic benign prostatic hyperplasia (bph) in patients who are in need of a liquid composition of terazosin

Dosage: SOLUTION

More Information on Dosage

TEZRULY family patents

Family Patents

17. Tyvaso patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11826327 UNITED THERAP Treatment for interstitial lung disease
Feb, 2042

(17 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Dosage Form(NDF) Jul 30, 2012
Orphan Drug Exclusivity(ODE) Jul 30, 2016
M(M-145) May 20, 2017
New Indication(I-856) Mar 31, 2024

Drugs and Companies using TREPROSTINIL ingredient

Market Authorisation Date: 30 July, 2009

Treatment: Method of treating pulmonary hypertension associated with interstitial lung disease by administering treprostinil or a salt thereof by inhalation using a device

Dosage: SOLUTION

How can I launch a generic of TYVASO before it's drug patent expiration?
More Information on Dosage

TYVASO family patents

Family Patents

18. Tyvaso Dpi patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11826327 UNITED THERAP Treatment for interstitial lung disease
Feb, 2042

(17 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) May 23, 2025

Drugs and Companies using TREPROSTINIL ingredient

Market Authorisation Date: 23 May, 2022

Treatment: Method of treating pulmonary hypertension associated with interstitial lung disease by administering treprostinil or a salt thereof by inhalation using a device

Dosage: POWDER

More Information on Dosage

TYVASO DPI family patents

Family Patents

19. Vevye patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US12059449 HARROW EYE Ophthalmic composition for treatment of dry eye disease
Apr, 2042

(17 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) May 30, 2026

Drugs and Companies using CYCLOSPORINE ingredient

Market Authorisation Date: 30 May, 2023

Treatment: Increase tear production in patients with keratoconjunctivitis sicca (dry eye).

Dosage: SOLUTION

More Information on Dosage

VEVYE family patents

Family Patents

20. Vivimusta patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11844784 AZURITY Stable pharmaceutical compositions of bendamustine
Jul, 2042

(17 years from now)




Drugs and Companies using BENDAMUSTINE HYDROCHLORIDE ingredient

Market Authorisation Date: 07 December, 2022

Treatment: NA

Dosage: SOLUTION

More Information on Dosage

VIVIMUSTA family patents

Family Patents

21. Xelstrym patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11559501 NOVEN PHARMS INC Transdermal amphetamine compositions with low levels of carbamate
Jan, 2042

(17 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Mar 22, 2025

Drugs and Companies using DEXTROAMPHETAMINE ingredient

Market Authorisation Date: 22 March, 2022

Treatment: NA

Dosage: SYSTEM

More Information on Dosage

XELSTRYM family patents

Family Patents

22. Zunveyl patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11795176 ALPHA COGNITION Solid forms of Alpha-1062 gluconate
Jan, 2042

(17 years from now)




Drugs and Companies using BENZGALANTAMINE GLUCONATE ingredient

Market Authorisation Date: 26 July, 2024

Treatment: Treatment of mild to moderate dementia of the alzheimer's type

Dosage: TABLET, DELAYED RELEASE

More Information on Dosage

ZUNVEYL family patents

Family Patents